Related Content
- Mylan to launch educational site about generic drugs
- Mylan gets approval for generic version of Vfend
- Report: State Medicaid programs can reap savings with increase in generic drug use
- Mylan's Hyzaar, Cozaar generics receive OK from FDA
- Report: Mylan looks to block Ranbaxy from making generic Lipitor
PITTSBURGH — Generic drug maker Mylan has released a version of a drug used to treat bacterial infections, the company said.
Mylan announced the launch of doxycycline hyclate delayed-release tablets in the 150-mg strength. The launch follows a decision by the U.S. District Court for the District of New Jersey that Mylan's product did not infringe patents covering the drug's branded version, Doryx. Warner Chilcott, which markets Doryx, had brought the case.
Doxycycline hyclate DR tablets had sales of about $264.1 million in 2011, according to IMS Health.
Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.
